Report Content
Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates and calculations
1.3 Forecast calculations
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Public sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Sickle cell disease treatment industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Treatment modality trends
2.1.4 Disease type trends
2.1.5 End-user trends
Chapter 3 Sickle Cell disease Treatment Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of sickle cell disease
3.2.1.2 Increasing R&D activities in drug development for sickle cell disease
3.2.1.3 Increasing healthcare expenditure and government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with the treatment
3.2.2.2 Side effects associated with sickle cell disease treatment drugs
3.3 Growth potential analysis
3.3.1 By treatment modality
3.3.2 By disease type
3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Sickle Cell Disease Treatment Market Estimates and Forecast, By Treatment Modality (USD Million)
5.1 Key trends, by treatment modality
5.2 Blood transfusion
5.3 Pharmacotherapy
5.3.1 By drug type
5.3.1.1 Hydroxyurea
5.3.1.2 Oxybryta
5.3.1.3 Adakveo
5.3.1.4 Endari
5.3.1.5 Other pharmacotherapies
5.3.2 By route of administration
5.3.2.1 Oral
5.3.2.2 Parenteral
5.4 Bone marrow transplant
Chapter 6 Sickle Cell Disease Treatment Market Estimates and Forecast, By Disease Type (USD Million)
6.1 Key trends, by disease type
6.2 Sickle cell anemia
6.3 Hemoglobin sickle C disease (HbSC)
6.4 Other disease types
Chapter 7 Sickle Cell Disease Treatment Market Estimates and Forecast, By End-user (USD Million)
7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users
Chapter 8 Sickle Cell Disease Treatment Market Estimates and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Switzerland
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of MEA
Chapter 9 Company Profiles
9.1 Pfizer, Inc.
9.2 Novartis AG
9.3 Emmaus Medical, Inc.
9.4 Medunik USA, Inc.
9.5 Bristol-Myers Squibb Company
9.6 Bluebird Bio, Inc.
9.7 Agios Pharmaceuticals
9.8 CRISPR Therapeutics
9.9 Vifor Pharma
9.10 Editas Medicine Inc.
